SEC Form 10-Q Summary
Filing entity: Aileron Therapeutics, Inc. (NASDAQ: ALRN), although the request metadata identifies Rein Therapeutics, Inc. The filing covers the quarter and six months ended June 30, 2020 and was filed August 5, 2020.
Business Context and Reporting Period
Aileron is a clinical-stage biopharmaceutical company developing ALRN-6924, a dual MDM2/MDMX inhibitor intended to protect healthy cells from chemotherapy-related toxicities. The principal program was a Phase 1b/2 trial in patients with extensive-disease small cell lung cancer receiving topotecan.
The company had no approved products and had generated no product revenue. Its operations remained focused on research, clinical development, intellectual property and corporate activities.
Financial Highlights
| Metric | Q2 2020 | Q2 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | None |
| Research and development expense | $2.488 million | $4.304 million | Down $1.816 million |
| General and administrative expense | $1.912 million | $3.075 million | Down $1.163 million |
| Total operating expenses | $4.400 million | $7.379 million | Down $2.979 million |
| Net loss | $4.390 million | $7.172 million | Improved $2.782 million |
| Net loss per share | $0.14 | $0.26 | Improved |
| Metric | Six Months 2020 | Six Months 2019 | Change |
|---|---|---|---|
| Research and development expense | $6.557 million | $8.478 million | Down $1.921 million |
| General and administrative expense | $4.719 million | $6.214 million | Down $1.495 million |
| Total operating expenses | $11.276 million | $14.692 million | Down $3.416 million |
| Net loss | $11.138 million | $14.385 million | Improved $3.247 million |
| Net loss per share | $0.38 | $0.68 | Improved |
| Net cash used in operating activities | $10.744 million | $13.193 million | Improved $2.449 million |
At June 30, 2020, cash and cash equivalents were $17.124 million, investments were $1.756 million and total cash, cash equivalents and investments were $18.880 million. Total assets were $26.125 million and total liabilities were $9.471 million. The company had an accumulated deficit of $209.273 million.
Cash, cash equivalents and restricted cash increased by $11.813 million during the first six months of 2020. Investing activities provided $11.297 million, primarily from investment maturities and sales. Financing activities provided $11.260 million, including equity offering proceeds and a $0.384 million Paycheck Protection Program loan.
The company had $0.384 million of PPP debt outstanding at June 30, 2020, consisting of $0.171 million classified as current and $0.213 million as non-current. Operating lease liabilities totaled $4.822 million.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined primarily because patient dosing in a prior Phase 2a palbociclib combination cohort was completed, certain earlier programs were discontinued or completed, and cost-reduction measures were implemented.
- General and administrative expense declined due to cost savings measures implemented in March 2020, including personnel reductions and lower administrative support costs.
- In June 2020, the company sold 10,162,059 common shares at $1.10 per share, generating approximately $11.178 million of gross proceeds and approximately $10.246 million after stated offering costs.
- During the first six months of 2020, the company sold 1,263,059 shares under its at-the-market agreement for $0.762 million of gross proceeds. The agreement was terminated in June 2020.
- Common shares outstanding increased from 27.810 million at December 31, 2019 to 39.262 million at June 30, 2020, reflecting substantial equity issuance and dilution.
- Nasdaq notified the company on June 11, 2020 that it had regained compliance with the $1.00 minimum bid-price requirement.
Guidance, Outlook, Risks and Unusual Items
- Management expected cash, cash equivalents and investments at June 30, 2020 to fund the current business plan into the fourth quarter of 2021. Nevertheless, the company disclosed substantial doubt about its ability to continue as a going concern without additional capital.
- The company planned to seek additional equity, debt, collaboration or other strategic financing. It had no committed external source of funds, and additional financing may be unavailable or dilutive.
- Management planned to report final dose-optimization data from the ALRN-6924 SCLC trial and preliminary schedule-optimization data in the fourth quarter of 2020.
- The company planned to initiate a healthy-volunteer study in the third quarter of 2020 to evaluate the timing and duration of ALRN-6924-induced cell-cycle arrest and expected initial data in the fourth quarter of 2020.
- Interim clinical findings announced in June 2020 indicated a protective effect against severe anemia and thrombocytopenia compared with historical controls. The filing cautioned that interim results may change and may not predict final outcomes.
- COVID-19 had not significantly affected first-half 2020 results, but could disrupt clinical enrollment, patient visits, trial monitoring, manufacturing and supply, regulatory activities and future access to capital.
- Key risks included failure of ALRN-6924 clinical trials, adverse safety or efficacy findings, regulatory delays, dependence on third-party manufacturers and clinical research organizations, intellectual-property challenges, competition and the need for substantial additional funding.
- The filing disclosed no material legal proceedings and no off-balance-sheet arrangements.
- The company’s board was authorized, subject to its discretion, to effect a one-for-five to one-for-25 reverse stock split before December 31, 2020.
Most Important Facts for Investors to Verify
- Confirm the correct issuer: the supplied filing is for Aileron Therapeutics, Inc., not Rein Therapeutics, Inc.
- Assess the going-concern disclosure and the company’s ability to raise capital before projected cash exhaustion.
- Track cash burn, remaining cash and investments, PPP loan forgiveness status and future equity issuance or dilution.
- Verify final results from the ALRN-6924 SCLC dose- and schedule-optimization cohorts against the preliminary findings.
- Monitor the impact of COVID-19 on trial enrollment, manufacturing, supply and regulatory timelines.
- Evaluate clinical, regulatory, manufacturing, intellectual-property and competitive risks surrounding ALRN-6924.
- Review any implementation of the authorized reverse stock split and continued Nasdaq listing compliance.